DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
CONTEXT: We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes. OBJECTIVE: The objective of the study was to compare effects of exenatide once weekly (ExQW) and exenatide twice daily (ExBID) on glycemic control, body weight, and safety. DESIGN: This was a 24-wk, randomized, open-label, comparator-controlled study. SETTING: The study was conducted at 43 sites in the United States. PATIENTS: The study population was 252 intent-to-treat patients with type 2 diabetes [baseline (mean ± SD): glycosylated hemoglobin (HbA1c) 8.4 ± 1.2%, fasting plasma glucose 171 ± 47 mg/dl, weight 96 ± 20 kg] that were drug naïve (19%) or previously treated with one (47%) or multiple (35%) oral antidiabetic medications. INTERVENTIONS: Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk. MAIN OUTCOME MEASURE: The change in HbA1c from baseline to wk 24 was measured. RESULTS: At 24 wk, ExQW produced significantly greater changes from baseline (least squares mean ± SE) vs. ExBID in HbA1c (-1.6 ± 0.1% vs. -0.9 ± 0.1%; P < 0.0001) and fasting plasma glucose (-35 ± 5 mg/dl vs. -12 ± 5 mg/dl; P = 0.0008). Similar reductions in mean body weight from baseline to wk 24 were observed in both groups (-2.3 ± 0.4 kg and -1.4 ± 0.4 kg). Both treatments were generally well tolerated. Transient and predominantly mild to moderate nausea, the most frequent adverse event, was less common with ExQW (14%) than with ExBID (35%). Injection-site reactions were infrequent, but more common with ExQW. No major hypoglycemia occurred. CONCLUSIONS: Continuous glucagon-like peptide-1 receptor agonism with ExQW resulted in superior glycemic control, with less nausea, compared with ExBID in patients with type 2 diabetes. Both groups lost weight.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Contrary to short-acting GLP-1RAs, human GLP-1 analogues induce a more marked reduction in HbA1c and fasting blood sugar and decrease the incidence of side effects such as nausea and vomiting; moreover, they have shown greater efficacy on cardiovascular mortality and morbidity [19, 20].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [20]
In the citing paper
“Contrary to short-acting GLP-1RAs, human GLP-1 analogues induce a more marked reduction in HbA1c and fasting blood sugar and decrease the incidence of side effects such as nausea and vomiting; moreover, they have shown greater efficacy on cardiovascular mortality and morbidity [19, 20].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [20]
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470 · cited 1×
“However, optimal treatment of diabetes must address both glycemic control and such comorbiditiesasobesity,hypertension,anddyslipidemia (2,3).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 3×
“0%, n (%) 34 (28) 38 (30) Mean SD FPG (mg/dl) 168 47 173 47 Mean SD duration of diabetes at screening (yr) 7 5 7 5”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 9×
“As in the case of ExBID, ExQW has been demonstrated to improve glycemic control and reduce body weight (15, 16).”
BackgroundMethodResultInfluentialSelf-citationRodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · cited 5×
“J Clin Endocrinol Metab, May 2011, 96(5):1301–1310 jcem.”
InfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Exenatide administered twice daily (ExBID), a wellcharacterized GLP-1 receptor agonist approved for use as an adjunct to diet and exercise, has been shown to promote glycemic control in patients with type 2 diabetes and produce weight loss; in addition, exenatide has been reported to improve cardiovascular risk factor…”
BackgroundBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 3×
“Gender, n (%) Male 68 (55) 77 (60) Age at consent (yr) Mean SD 55 10 56 11 Minimum, maximum 23, 79 23, 83 Race/ethnicity, n (%) Caucasian 68 (55) 81 (63) Black 9 (7) 6 (5) Asian 5 (4) 5 (4) Hispanic 41 (33) 37 (29) Mean SD weight (kg) 94.”
BackgroundResultBergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Self-citationKolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Self-citationKlein, S., Sheard, N. F., Pi-Sunyer, X., Daly, A., Wylie-Rosett, J., Kulkarni, K., & Clark, N. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2067 · Cited by 540
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“substitutions (32) that is administered once daily, has been”
BackgroundKim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 446
Self-citationDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 3×
“Although mean improvements in HbA1c were greater in the DURATION-1 study, the magnitude of the difference between ExQW and ExBID was greater in the current study and the reductions in HbA1c observed in the current 24-wk study are consistent with those observed in two 26-wk studies of ExQW [DURATION-2 and DURATION-3 (2…”
BackgroundResultSelf-citationKolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373 · cited 2×
“pared with ExBID (31), and ExQW (23) demonstrated su-”
BackgroundMethodFineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · cited 2×
“HbA1c was measured by HPLC. Plasma concentrations of antibodies to exenatide were measured using a validated ELISA (20).”
MethodSelf-citationEgan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
Fineman, M. S., Shen, L. Z., Taylor, K., Kim, D. D., & Baron, A. D. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.499 · Cited by 227 · cited 2×
“Theseresultsareconsistent with the results of DURATION-1 and with observations that a gradual increase in plasma exenatide concentrations may decrease the incidence of gastrointestinal adverse events (16, 30).”
ResultSelf-citationKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
Larsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171 · cited 2×
“tion (9), demonstrating the potential role of continuous GLP-1 receptor agonism in improving glycemic control in type 2 diabetes (10).”
BackgroundA useful testing strategy in phase iii trials: combined test of superiority and test of equivalence
Morikawa, T., & Yoshida, M. (1995) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409508835115 · Cited by 137 · cited 2×
“4%; superiority was demonstrated if the CI was below zero (21).”
BackgroundRachman, J., Gribble, F. M., Barrow, B. A., Levy, J. C., Buchanan, K. D., & Turner, R. C. (1996) · Diabetes · doi:10.2337/diab.45.11.1524 · Cited by 119 · cited 1×
“tion (9), demonstrating the potential role of continuous GLP-1 receptor agonism in improving glycemic control in type 2 diabetes (10).”
BackgroundNauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M., & Balena, R. (2009) · Diabetes Care · doi:10.2337/dc08-1961 · Cited by 117
Best, J. H., Boye, K. S., Rubin, R. R., Cao, D., Kim, T. H., & Peyrot, M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02752.x · Cited by 97 · cited 2×
“In addition, once-weekly administration has been reported to reduce patient burden by providing patients with a weekly dosing regimen (17).”
Background
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“49 GLP-1RA is primarily used for the treatment of T2DM 68 and works by mimicking the action of the naturally occurring hormone GLP-1, which is released by the intestines in response to food intake.”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“Exenatide LAR: Administration of exenatide LAR was proved more effective than highest dose of exenatide twice-daily [193,194] , sitagliptin and pioglitazone [195] , and insulin glargine [196] in T2DM patients treated with oral hypoglycaemic agents.”
BackgroundAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Metadata
- Authors
- Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L.
- Affiliations
- Texas Diabetes & Endocrinology (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Blevins, Thomas
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-05
- Volume
- 96
- Issue
- 5
- Pages
- 1301-1310
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2043900831
- Cited by
- 448
- References
- 37
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 18 · 2023: 7 · 2022: 15 · 2021: 13 · 2020: 17 · 2019: 16 · 2018: 30 · 2017: 34 · 2016: 36 · 2015: 43 · 2014: 53 · 2013: 56 · 2012: 60
- FWCI
- 49.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, weekly dosing, twice-daily dosing, GLP-1 receptor agonists, type 2 diabetes, glycemic control, HbA1c, fasting blood glucose, body weight, nausea, injection site reactions, hypoglycemia, drug-naive patients
- MeSH terms
- Exenatide, Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Chromatography, High Pressure Liquid, Combined Modality Therapy, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Enzyme-Linked Immunosorbent Assay, Exercise Therapy, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Peptides, Risk Factors, Venoms, Weight Loss, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.